Sterling Biotech Limited reported unaudited standalone earnings results for three months and six months ended September 30, 2016. For the quarter, the company’s net sales/income from operations was INR 945.871 million compared to INR 1,143.778 million a year ago. Loss from operations before other income and finance costs was INR 721.670 million compared to INR 548.042 million a year ago. Loss from ordinary activities after finance costs but before tax was INR 1,674.730 million compared to INR 1,389.239 million a year ago. Net loss was INR 1,095.130 million or INR 2.53 per diluted share before and after extraordinary items compared to INR 908.439 million or INR 2.10 per basic and diluted share before and after extraordinary items for the same period a year ago. For the six months, the company’s net sales/income from operations was INR 1,975.905 million, loss from operations before other income and finance costs was INR 1,264.678 million, loss from ordinary activities after finance costs but before tax was INR 3,014.418 million and net loss was INR 1,970.518 million or INR 4.55 per diluted share before and after extraordinary items.